Real-world effectiveness of dupilumab in patients with asthma

杜皮鲁玛 医学 哮喘 恶化 呼出气一氧化氮 内科学 药方 回顾性队列研究 支气管收缩 药理学
作者
Michael S. Blaiss,Eugene R. Bleecker,Juby A. Jacob‐Nara,Radhika Nair,Mei Sheng Duh,Zhixiao Wang,Richard H. Stanford,Xavier Soler,Megan Hardin,Mingchen Ye,Anamika Khanal,Kinga Borsos
出处
期刊:Annals of Allergy Asthma & Immunology [Elsevier BV]
卷期号:132 (4): 463-468.e1 被引量:5
标识
DOI:10.1016/j.anai.2023.11.006
摘要

Background Dupilumab is approved as an add-on maintenance therapy for patients (≥6 years) with moderate-to-severe asthma. Better understanding of real-world effectiveness is needed. Objective To characterize the real-world effectiveness of dupilumab in asthma management. Methods This retrospective study included patients (≥12 years of age) diagnosed with asthma, initiating dupilumab between November 2018 and September 2020. The study used a US electronic medical record database (TriNetX Dataworks, Cambridge, Massachusetts). Asthma exacerbation rates before and after the initiation of dupilumab were analyzed using generalized estimating equations models with Poisson probabilistic link to estimate incidence rate ratios (IRRs). Sensitivity analyses were conducted based on previous exacerbation data, eosinophil levels, history of atopic dermatitis or chronic rhinosinusitis with nasal polyps, previous use of biologics, and presence of SARS-CoV-2 (COVID-19). Results A total of 2400 patients initiating dupilumab met all study criteria. After initiation of dupilumab, risk of asthma exacerbation was reduced by 44% (IRR, 0.56; 95% CI, 0.47-0.57; P = <0.0001) and systemic corticosteroid prescriptions by 48% (IRR, 0.52; 95% CI, 0.48, 0.56; P = <0.0001) compared with those before initiation of dupilumab. Adjustment for COVID-19 showed a greater reduction in asthma exacerbations (IRR, 0.50; 95% CI, 0.45-0.55; P = <0.0001). Conclusion Current real-world efficacy evidence indicates that dupilumab reduces asthma exacerbations and total systemic corticosteroid prescriptions in clinical practice. The effectiveness of dupilumab was observed independent of exacerbation history, eosinophil levels, or COVID-19 impact.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助顺心的飞飞采纳,获得10
刚刚
Owen应助CQ采纳,获得10
1秒前
外向的新儿完成签到,获得积分10
1秒前
小马甲应助孟令涛采纳,获得10
2秒前
2秒前
yyyalles应助车厘子采纳,获得10
2秒前
kecheng应助欧欧欧导采纳,获得10
3秒前
3秒前
852应助wzh1745采纳,获得10
3秒前
3秒前
一天完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
4秒前
GHOMON完成签到,获得积分10
5秒前
5秒前
语亦菲扬921完成签到,获得积分10
5秒前
丘比特应助liguanyu1078采纳,获得10
5秒前
janie发布了新的文献求助10
5秒前
byzhao19发布了新的文献求助10
5秒前
JamesPei应助大神装采纳,获得10
5秒前
水木应助hsialy采纳,获得10
5秒前
JY完成签到,获得积分20
6秒前
7秒前
顺利山柏完成签到 ,获得积分10
7秒前
7秒前
8秒前
8秒前
bing发布了新的文献求助10
8秒前
BenQiu发布了新的文献求助10
8秒前
半柚应助纯情的亦竹采纳,获得10
8秒前
txg发布了新的文献求助10
9秒前
yio关闭了yio文献求助
10秒前
zimablue发布了新的文献求助10
10秒前
10秒前
福尔摩云发布了新的文献求助30
10秒前
niunai完成签到 ,获得积分10
11秒前
JY发布了新的文献求助10
11秒前
mmddlj完成签到 ,获得积分10
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970949
求助须知:如何正确求助?哪些是违规求助? 3515634
关于积分的说明 11179061
捐赠科研通 3250769
什么是DOI,文献DOI怎么找? 1795474
邀请新用户注册赠送积分活动 875831
科研通“疑难数据库(出版商)”最低求助积分说明 805188